The article focuses on the development of a biomarker detector called T2 Biosystems Inc. dubbed as T2Dx. It mentions that the technology has detected fungal pathogens in samples of blood during a meeting. T2's chief executive John McDonough states that the technology is powerful and the company is in a good position. It adds that a nanoparticle-based detection system for protein diagnostic was developed by Nanosphere Inc.